Our Technology

  • The Perima graft's ability to resist infection and biofilm compares with autogenous veins 

  • The product shows growth of endothelium, resistance to biofilm and high primary/secondary patency

  • Decreased surgery time ensures higher patient survival rates

Our technology is based on the use of completely biological materials. These grafts permit the growth of endothelium and mesothelium, while synthetic grafts create an external collagen layer and reduce the graft's ability to actively fight infection.

The use of autologous veins poses many risks, like the prolonging of life-threatening surgeries, increased patient surgery trauma and an elevated risk of complications.

Our technology prevents the growth of biofilm, a significant complication in Infective Endocarditis. Biofilm vegetation of grafts can only be eliminated through an antibiotic concentration of 900-1500 times more than normal, a dose lethal to patients (see the clinical manual).

The graft's complete biocompatibility and resistance to biofilm, enables the growth of endothelium.  Since the graft does not degenerate, the diameter of the graft remains consistent and unchanged. This has not been seen on any other grafts currently used in cardiac surgery.

Clinical studies that included use of the Perima on a compassionate basis, showed the graft has an 82% primary patency and 100% secondary patency (see the clinical manual).

**Perima is a trademarked name